FundingHealthcare & Life Sciences
Orange Health Labs raises ₹277 crore Series C
By Abha Lohia · Editor ·
Orange Health valuation
Orange Health was valued at ₹1,950 Cr (2026). Orange Health reported revenue of ₹138 Cr in FY26, with a net loss of ₹81 Cr, as reported by Your Story and Entrackr on 22 June 2026.
| Valuation (2026) | ₹1,950 Cr |
|---|---|
| Revenue (FY26) | ₹138 Cr |
| Net loss (FY25) | ₹81 Cr |
Orange Health: revenue, valuation and funding and every story →
Series CBengaluruFounded 2020
- Orange Health Labs is a full-stack diagnostics platform offering at-home sample collection and own labs
- It raised ₹277 crore (~$30 million) in Series C funding led by Iron Pillar India
- The company has served over 3 million orders and achieved 65% YoY revenue growth to ₹138 crore in FY26
What happened
- Orange Health Labs has raised ₹277 crore (~$30 million) in a Series C funding round.
- The round was led by Iron Pillar India, which invested ₹156 crore (~$16 million).
- Other participants include Crescent Enterprises (₹37.7 crore), Bertelsmann (₹21.8 crore), Accel India (₹8 crore), General Catalyst (₹1.8 crore), Good Capital (₹15.5 crore), and Paramark Frontier Fund (₹37 crore).
- The post-money valuation is approximately ₹1,950 crore ($205 million).
- Prior to this round, the company had raised about $50 million in total funding.
- Previous rounds include a $12 million round in 2024 led by Amazon Sambhav Venture Fund and a $25 million Series B in 2022 led by General Catalyst and Bertelsmann India Investments.
- Accel India remains the largest external shareholder with a 15.49% stake post-Series C, while Iron Pillar India holds 8.0%.
Why it matters
- India's clinical diagnostics market is expected to reach $4,427.5 million by 2030 at a 10% CAGR (Grand View Research).
- Orange Health Labs has achieved 65% YoY revenue growth to ₹138 crore in FY26, with an ARR of ₹180 crore.
- Its Bengaluru operations are at 20% EBITDA profitability, and all other city operations are operationally profitable.
- The company competes with established players like Dr Lal PathLabs, Redcliffe Labs, and Metropolis India.
The business
- Orange Health Labs is a full-stack diagnostics platform offering at-home sample collection and its own NABL-accredited and ICMR-certified labs.
- Customers book tests via the app or website, and an eMedic arrives within 30 minutes for home collection.
- Reports are delivered within 6 hours for 98% of orders.
- The company has 750 eMedics, who hold a diploma or degree in medical lab technology and undergo about 100 hours of training.
- It has served over 3 million orders to date and has over 50,000 Google reviews averaging 4.9/5.
- Its Net Promoter Score has been above 85 since inception.
- The platform handles blood, urine, and genetic tests, and has expanded to Delhi, Mumbai, Hyderabad with over 75 walk-in collection centres since 2024.
- Revenue split: 70% from direct consumers via app/website, 30% from corporate partnerships, insurers, employers, and platforms like Amazon (exclusive partner for pharmacy and diagnostics).
- It has over 150 corporate partners and over 2,000 clinics onboarded.
- The company uses in-house software with AI for eMedic assignment, logistics, and report processing, and is ISO 27001 and SOC 2 certified.
The founders
- Previously worked in telehealth and diagnostics at Practo.
- Was inspired to start the company after his wife and daughter contracted dengue in 2019.
- Former McKinsey consultant and investor.
Who put in money
- Iron Pillar India lead — Growth-stage venture capital firm investing in Indian tech companies.
- Crescent Enterprises participated — UAE-based diversified business group with a venture capital arm.
- Bertelsmann participated — German media, services, and education conglomerate with an investment arm.
- Accel India participated — Venture capital firm; largest external shareholder with 15.49% stake post-Series C.
- General Catalyst participated — US-based venture capital firm.
- Good Capital participated — Early-stage venture capital firm focused on Indian startups.
- Paramark Frontier Fund participated — Venture capital fund investing in high-growth startups.
In numbers
₹277 CrSeries C amount · 2026
₹1,950 CrPost-money valuation · 2026
$50MTotal funding prior to Series C · 2026
₹138 CrFY26 revenue · 2026
₹180 CrFY26 ARR · 2026
65%FY26 YoY revenue growth · 2026
₹84 CrFY25 revenue · 2025
₹81 CrFY25 loss · 2025
3M+Orders served · 2026
4.9/5Google reviews average · 2026
85+Net Promoter Score · 2026
750eMedics · 2026
150+Corporate partners · 2026
2,000+Clinics onboarded · 2026
75+Walk-in collection centres · 2026
15.49%Accel India stake post-Series C · 2026
8.0%Iron Pillar India stake post-Series C · 2026
What happens next
- The company plans to expand to new cities, strengthen its omnichannel presence, and widen test categories.
Earlier rounds
- 2024 · Series · $12M · led by Amazon Sambhav Venture Fund
- 2022 · Series B · $25M · led by General Catalyst and Bertelsmann India Investments
Up against
Dr Lal PathLabsRedcliffe LabsMetropolis India
Words to know
- EBITDA
- Earnings Before Interest, Taxes, Depreciation, and Amortisation – a measure of a company's operating profitability.
- ARR
- Annual Recurring Revenue – the yearly value of subscription-based revenue normalised from a shorter period.
- NABL
- National Accreditation Board for Testing and Calibration Laboratories – Indian accreditation for testing labs.
- ICMR
- Indian Council of Medical Research – the apex body for biomedical research in India.
The numbers around it
Orange Health has 2 funding rounds in StopDown's archive.
| When | Round | Amount | Led by |
|---|---|---|---|
| 20 August 2026 | Round | $30 million |
Healthcare & Life Sciences in June 2026: 11 rounds with a disclosed amount, $118 million in all; the biggest was Vetic ($40 Mn). Every sector this year →
Other articles talking about it
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.
- Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.
- Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Orange Health → · All startup news on 22 June 2026 →
Is this Orange Health? Get your “Featured on StopDown” badge →